Gainers
-
Altimmune, Inc. (NASDAQ: ALT) rose 38.1
percent to $4.17 in pre-market trading after gaining 12.27 percent on Wednesday.
-
OHR Pharmaceutical, Inc. (NASDAQ: OHRP) rose 16.2 percent to $3.60 in pre-market trading after surging 44.19
percent on Wednesday.
-
GrafTech International Ltd. (NYSE: EAF)
rose 13.7 percent to $13.20 in pre-market trading after reporting withdrawal of proposed secondary offering due to market
conditions.
-
Bio-Path Holdings, Inc. (NASDAQ: BPTH)
rose 13.4 percent to $13.63 in pre-market trading after jumping 160.46 percent on Wednesday.
-
Alaska Communications Systems Group Inc (NASDAQ: ALSK) shares rose 13 percent to $1.92 in pre-market trading after the company
reported better-than-expected Q4 EPS results.
-
Health Insurance Innovations Inc (NASDAQ: HIIQ) rose 11.4 percent to $39.09 in pre-market trading after the company
reported better-than-expected earnings for its fourth quarter and issued strong full-year 2019 guidance.
-
Guidewire Software, Inc. (NYSE: GWRE)
rose 9.4 percent to $94.60 in pre-market trading after the company reported better-than-expected Q2 EPS and sales results and
issued Q3 sales guidance above analyst estimates.
-
Mechel PAO (NYSE: MTL) rose 4.7 percent
to $2.25 in pre-market trading after declining 4.87 percent on Wednesday.
-
NXP Semiconductors N.V. (NASDAQ: NXPI)
shares rose 3.5 percent to $95.06 in pre-market trading.
-
DBV Technologies S.A. (NASDAQ: DBVT)
rose 3.4 percent to $8.68 in pre-market trading after declining 10.35 percent on Wednesday.
-
J.Jill, Inc. (NYSE: JILL) rose 2.3
percent to $6.89 in pre-market trading after gaining 14.63 percent on Wednesday.
Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.
Check out these big penny stock gainers and
losers
Losers
-
Aptevo Therapeutics Inc (NASDAQ: APVO)
fell 36.5 percent to $0.94 in pre-market trading after reporting a proposed public offering of common stock and warrants.
-
Bridgepoint Education, Inc. (NYSE: BPI)
shares fell 11.9 percent to $8.31 in pre-market trading after the company disclosed that Audit Committee has concluded
previously-issued financial statements for 3-, 9-months ended September 30, 2018. Bridgepoint expects Q4 adjusted EPS of
$(0.25)-$(0.23) and sales of $93.7 million-$94.7 million.
-
CooTek (Cayman) Inc. (NYSE: CTK) fell 9.5
percent to $10.00 in pre-market trading after the company reported Q4 results.
-
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) fell 9.3 percent to $16.60 in pre-market trading. Apellis Pharma priced
its 6 million share offering at $17 per share.
-
Ballard Power Systems Inc. (NASDAQ: BLDP) fell 7.9 percent to $3.05 in pre-market trading following Q4 results.
-
Xunlei Limited (NASDAQ: XNET) fell 7.3
percent to $4.30 in pre-market trading after reporting Q4 results.
-
Rio Tinto plc ADR (NYSE: RIO) fell 6.7
percent to $55.22 in pre-market trading. Societe Generale downgraded Rio Tinto from Hold to Sell.
-
Epizyme, Inc. (NASDAQ: EPZM) fell 6
percent to $11.31 in pre-market trading. Epizyme priced its 10 million share common stock offering at $11.50 per share.
-
International Game Technology PLC (NYSE: IGT) fell 5.7 percent to $16.10 in pre-market trading following downbeat Q4
results.
-
SharpSpring, Inc. (NASDAQ: SHSP) fell
5.4 percent to $13.25 in pre-market trading after reporting a proposed public offering of common stock.
-
China Biologic Products Holdings, Inc. (NASDAQ: CBPO) fell 4.9 percent to $79.70 in pre-market trading following Q4 results.
-
Allergan plc (NYSE: AGN) fell 4.6 percent
to $131.17 in pre-market trading after announcing Phase 3 results for Rapastinel. Three acute pivotal studies did not meet its
primary endpoint.
-
Vale S.A. (NYSE: VALE) fell 4.1 percent
to $11.98 in pre-market trading.
-
Horizon Pharma plc (NASDAQ: HZNP)
shares fell 4 percent to $24.45 in pre-market. Horizon Pharma priced its 12.244 million share public offering of ordinary
shares at $24.50 per share.
-
American Eagle Outfitters, Inc. (NYSE: AEO) shares fell 3.2 percent to $20.65 in pre-market trading. American Eagle
reported upbeat earnings for its fourth quarter, while sales missed estimates. The company issued weak first-quarter earnings
guidance.
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.